Navigation Links
Discovery in liver cancer cells provides new target for drugs
Date:3/22/2011

Richmond, Va. (March 23, 2011) Researchers at Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) have discovered a novel mechanism in gene regulation that contributes to the development of a form of liver cancer called hepatocellular carcinoma (HCC). Currently, there is virtually no effective treatment for HCC, and this breakthrough identifies a promising new target for therapeutic intervention.

In the journal Hepatology, Devanand Sarkar, M.B.B.S., Ph.D., Harrison Endowed Scholar in Cancer Research at VCU Massey Cancer Center, a Blick scholar and assistant professor in the Department of Human and Molecular Genetics and a member of the VIMM at VCU School of Medicine, describes for the first time how RNA-induced silencing complex (RISC) contributes to the development of liver cancer.

RISC is an important factor in post-transcriptional gene regulation, which occurs between transcription (where DNA is converted to RNA) and translation (where RNA is converted to protein). These processes regulate functions such as cellular growth, division and death. Sarkar and his team identified the proteins AEG-1 and SND1 as factors that increase RISC activity and lead to the development of liver cancer.

For years, Sarkar has been studying the role of AEG-1 in cancer with his collaborator on this research, Paul B. Fisher, M.Ph., Ph.D., Thelma Newmeyer Corman Endowed Chair in Cancer Research at VCU Massey, professor and chair of the Department of Human and Molecular Genetics and director of the VIMM.

"AEG-1 works as a scaffold protein," says Sarkar. "If you think about scaffolding outside of a biological setting, its function is to help facilitate things like construction. In this case, AEG-1 was found to work with another protein, SND1, to provide the scaffold for the formation of RISC. Since both AEG-1 and SND1 are increased in HCC, the net effect is increased RISC activity."

The study clearly identifies SND1 as a novel regulator of liver cancer. As SND1 is a molecule that can be inhibited by drugs, Sarkar's findings open up a novel avenue for treating liver cancer by targeting SND1.

"RISC works by degrading tumor-suppressor mRNAs, which transmit genetic information in a cell that prevents the formation of tumors. This allows other cancer-causing factors to go unchecked and aid tumor growth," says Sarkar. "Since we've shown that RISC activity is higher in cancer cells than normal, healthy cells, we're hopeful that inhibiting SND1 to decrease RISC activity will do little, if any, damage to healthy liver cells while stopping cancer progression."

Sarkar's team is working hard to find the most clinically-relevant SND1 inhibitors. Once these are found, the researchers will need to prove their effectiveness in several more experiments. The ultimate goal is to move these findings to Phase I clinical trials for patients with liver cancer.


'/>"/>

Contact: John Wallace
wallacej@vcu.edu
804-628-1550
Virginia Commonwealth University
Source:Eurekalert

Related medicine news :

1. Finding of long-sought drug target structure may expedite drug discovery
2. New laser technique opens doors for drug discovery
3. LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus
4. Clinical observation leads to lung cancer discovery
5. New weight loss discovery by Harvard scientists moves us closer to the Pill for obesity
6. Leicester leads on heart attack genetic link discovery
7. Discovery of new gene mutation in schizophrenia offers a new target for drug therapies
8. UT MD Anderson discovery wins 2010 Cozzarelli Prize
9. Biomarker discovery may lead to reliable blood test for ectopic pregnancy
10. Washington Life Sciences Discovery Fund announces grants to commercialize promising technologies
11. Discovery May Explain Why Brain Cancer Is So Hard to Treat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: